Ph3 Study of ZL-1310 vs. Investigator's Choice Chemo in 2nd line ES SCLC
Phase
Phase III Clinical Trial
Condition(s)
Lung Cancer
Trial Number
07218146
Trial Status
OPEN
Study Overview
A Randomized Open-Label Phase 3 Study of ZL-1310 a DLL3 Antibody-Drug Conjugate (ADC) Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
